Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Insilico Starts China-US Phase II Trials of AI-Discovered Therapy for Lung Fibrosis

publication date: Jun 27, 2023

Insilico Medicine, a generative artificial intelligence-driven biotech, has dosed the first patients in a Phase II trial of INS018_055, the world's first anti-fibrotic inhibitor discovered and designed using generative AI. With potential to be a first-in-class drug, INS018_055 is aimed at treating Idiopathic Pulmonary Fibrosis, a chronic lung disease. The candidate is a small molecule inhibitor with a novel target discovered by Insilico's target identification engine, PandaOmics, and a novel molecular structure designed by its generative chemistry engine, Chemistry42. Insilico has operations in Hong Kong and New York. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital